1. Home
  2. IDCC vs ABVX Comparison

IDCC vs ABVX Comparison

Compare IDCC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InterDigital Inc.

IDCC

InterDigital Inc.

N/A

Current Price

$289.99

Market Cap

6.6B

Sector

Miscellaneous

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$87.96

Market Cap

7.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IDCC
ABVX
Founded
1972
2013
Country
United States
France
Employees
N/A
N/A
Industry
Multi-Sector Companies
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.7B
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
IDCC
ABVX
Price
$289.99
$87.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
12
Target Price
★ $462.67
$163.58
AVG Volume (30 Days)
198.4K
★ 822.0K
Earning Date
10-29-2026
09-21-2026
Dividend Yield
★ 1.02%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 7.86
N/A
Revenue
★ $307,404,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,695.54
P/E Ratio
$37.45
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$249.14
$69.81
52 Week High
$387.30
$148.83

Technical Indicators

Market Signals
Indicator
IDCC
ABVX
Relative Strength Index (RSI) 38.72 46.03
Support Level $272.01 $83.83
Resistance Level $296.49 $97.99
Average True Range (ATR) 12.81 3.62
MACD -1.97 0.83
Stochastic Oscillator 12.23 46.81

Price Performance

Historical Comparison
IDCC
ABVX

About IDCC InterDigital Inc.

InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: